The application relates to a pharmaceutical combination consisting essentially of a B-Raf inhibitor of Formula (I) or a pharmaceutically acceptable salt thereof, and a second inhibitor which is a PI3 kinase inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound F), or a pharmaceutically acceptable salt thereof and (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({ 4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl} -amide) (Compound X), or a pharmaceutically acceptable salt thereof, wherein the combination is adapted for administration simultaneously or sequentially.
